News

Nanotech: what makes investors bite

Investing in technology that's a few years from commercialisation can be tricky. Lori Valigra finds out how some venture capitalists sort the wheat from the chaff.

Lab Notes

On inventive Californians, technology transfer, how to approach the business press, and other insights into R&D management.

The beauty of it

"Scientific work … must be done for itself, for the beauty of science." Marie Curie, chemist & physicist (1867 - 1934)

An end to France's biotech drought?

It has been six years since a French biotech company made a stock market debut – and now two, BioAlliance and ExonHit, are doing so. Is the European market reawakening?